Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico
TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusive rights in Mexico for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery. Clobetasol propionate ophthalmic suspension, 0.05% (APP13007) was approved by the U.S. Food and Drug Administration (FDA) in 2024. APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform. The novel formulation enables a convenient and straightforward dosing regimen, while providing rapid and sustained relief of inflammation and pain, which in Phase 3 trials proved statistically and clinically superior to its matching placebo (p<0.001).
(PRNewsfoto/Formosa Pharmaceuticals Inc.,)
"Having started our journey together in 2024, Formosa Pharma is pleased to expand the partnership with Apotex to include Mexico." said Erick Co, President and CEO of Formosa Pharmaceuticals. "Our experience with Apotex's Canadian team underscored their commitment to branded and differentiated ophthalmology products, giving us full confidence that APP13007 will reach ophthalmologists and patients in Mexico as swiftly as possible."
"At Apotex, we are committed to delivering access to medicines and health products, and unlocking new possibilities for patients through partnerships. We are pleased to bring access to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) to the Mexican market upon regulatory approval. Our agreement with Formosa Pharmaceuticals further demonstrates Apotex's leading position as partner of choice in the Americas for pharmaceutical licensing and product acquisitions as we continue to execute our Journey of Heath growth strategy," said Alok Kanti, President, Apotex International.
About Formosa Pharmaceuticals, Inc.
Formosa Pharmaceuticals, Inc. (6838.TWO) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which APP13007 was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration. Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilization of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in delivery and penetration to target tissues. For more details about Formosa Pharma and APNT®, visit www.formosapharma.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
India central bank's large rate cut squeezes forward premiums, leaves rupee vulnerable, analysts say
By Nimesh Vora and Jaspreet Kalra MUMBAI (Reuters) -The Reserve Bank of India's surprise outsized rate cut last week will leave the rupee vulnerable to further depreciation by pressuring already depressed foreign exchange forward premiums, several analysts said on Monday. The rupee has underperformed its Asian peers in 2025 amid weak capital flows. A narrowing interest rate differential — with the U.S. Federal Reserve moving slower than the RBI in cutting rates — suggests the Indian currency may continue to lag. MARKET REACTION The 1-month U.S. dollar/rupee forward premium — typically more sensitive to liquidity conditions — fell to 7.5 paisa, its lowest level since November. Meanwhile, the 1-year premium, which is more responsive to rate differential between the U.S. and India, declined to 1.5250 rupees, marking its lowest level in nearly a year. GRAPHIC: WHY IT'S IMPORTANT A drop in dollar/rupee forward premiums makes the rupee less attractive for carry trades, and diminishes the incentive for exporters to hedge future receivables. At the same time, it raises the likelihood that importers—who typically hedge near-term payment obligations—will step up their hedging activity. The decline in premiums - a less favourable rate differential between the U.S. and India - could leave the rupee open to sharper depreciation. CONTEXT Against the backdrop of benign inflation and the need to support growth, the Reserve Bank of India last Friday delivered a larger-than-expected 50 basis point rate (bps) cut, exceeding the 25 bps anticipated by economists. In a further easing move, the central bank slashed the cash reserve ratio for banks. KEY QUOTES "One thing the rupee had going for it is that it offered attractive carry ... with the 50-bps rate cut from the RBI, carry attraction has been reduced," Mitul Kotecha, head of FX and EM macro strategy Asia at Barclays, adding that in an environment where investors are again focussed on carry, the rupee's appeal has been diminished. Falling premiums can be a "mild added headwind" for the rupee amid globally elevated yields, Dhiraj Nim, FX strategist at ANZ Research, said, and pointed out that if India growth data weaken, there could be scope for one more rate cut.
Bloomberg
an hour ago
- Bloomberg
Japan Should Use Asia Trade Bloc in US Talks, Party Chief Says
Japan should take a bigger role in a regional free trade agreement and use its expansion as a bargaining tool in tariff negotiations with the US, the leader of the country's largest opposition party said on Monday. Yoshihiko Noda, president of the Constitutional Democratic Party of Japan, was speaking to reporters in Tokyo after the country's chief negotiator returned from a fifth round of talks in Washington with little sign of a reprieve from US tariffs.
Yahoo
an hour ago
- Yahoo
"I'm not worried about our competitors": What Qualcomm's Snapdragon strategy says about Intel, Apple, and AMD
When you buy through links on our articles, Future and its syndication partners may earn a commission. Even if semiconductor giant Qualcomm likely faces a two-year gap between releases of its groundbreaking Snapdragon X platform — an eon in the hyper-competitive silicon market — the company's Snapdragon chief says he isn't worried. "I'm not worried about our competitors coming out with something," Qualcomm's Alex Katouzian told Laptop Mag this week at the Computex conference in Taipei. Katouzian is the General Manager of mobile, compute, and XR, and is responsible for execution on the Snapdragon chips. He believes the Snapdragon platform is powerful enough to survive the delay between the company's first- and second-generation computer chips, which have taken on the unofficial moniker "Snapdragon X2." "We're sustained in performance-per-watt, and we have relationships that are strong across retail and commercial, and we have marketing campaigns that are now very much concentrated on Snapdragon," Katouzian said. During their keynote at Computex, Qualcomm leaders tried to keep momentum by driving attention toward the Snapdragon Summit, scheduled for September 23-25 in Hawaii. At that summit, Qualcomm is expected to introduce "our next-generation solution," Katzouzian said. Questions about the second-generation Snapdragon X Elite chipset were answered with "come to Snapdragon Summit." Nevertheless, one question loomed over the keynote: Will Qualcomm be left behind with a two-year gap between generations? After all, Qualcomm announced the first Snapdragon X Elite chips at the Snapdragon Summit in 2023 and released them the following June. If Qualcomm repeats that pace, the next Snapdragon X chip won't be in laptops until June 2026. Qualcomm officially launched the Snapdragon X series with the X Elite and X Plus platforms last spring, between Microsoft Build in May and Computex in June 2024. In late 2024 and early 2025, Qualcomm announced additional X Plus chipsets and the budget X variants. "We introduced our solution at Computex that would already have designs that we launched in May with Microsoft last year," Katouzian said. "And so, we're only in the market for nine months. I think a platform such as X Elite, X Plus, X — it needs more than nine months to become mature in multiple designs and SKUs." Katouzian compared the release cycle to the Apple iPhones of yore, which used to follow a two-year "tick-tock" cycle, where a significant upgrade is announced every two years. By that logic, 2025 is Snapdragon's "tock" year. "I think it's OK to come in as a tick-tock," he said. "We come in and then four months from now we're going to introduce our next-generation solution, and then it'll ramp into market early 2026. As long as people and OEMs understand that this continuous advantage is coming, I'm OK." Since the first Copilot+ systems launch in June 2024, all of Qualcomm's competitors have released new chipset generations, and some are expected to hit their second generation since the X Elite this fall. Intel's Panther Lake chipsets are on track to bring the Intel Core Ultra brand into its 300 series this fall, and Apple is expected to launch the M5 chipset any time between this summer and fall. While Katouzian and CEO Cristiano Amon appear to believe the Snapdragon portfolio is strong enough to weather the oncoming storm, their new ad campaign tells a different story. If Qualcomm weren't worried about the competition or the arrival of Snapdragon X2, would they really need to keep building ads around what I found to be not-quite-accurate data? Even during this "tock" year, laptops and mini-PCs are continuing to debut with Snapdragon chips. The HP OmniBook 5 is a recent example. It's not like the company isn't still working with partners to get more systems out into the market. However, those systems are rocking 5-11 months old chipsets, depending on which slice of the Snapdragon X series we're considering. In the meantime, Intel, AMD, and Apple are all releasing newer silicon, making Qualcomm systems look less like a disruptor in the market and more like yesterday's news. This means the second-generation Snapdragon X series chipsets need to make as big a splash as the first-generation chipsets, if not more, to recapture public attention. Jensen Huang at Computex: "It's not because we don't love GeForce, GeForce got us here." The Acer Swift X 14, a favorite of creators, is being refreshed for 2025 The Asus ProArt P16 nails local AI and beats MacBooks — but it doesn't come cheap
